Skip to main content Back to Top
Advertisement

5/20/2020

Heparin Sodium Premixed Bags

Products Affected - Description

    • Heparin Sodium solution for injection, Fresenius Kabi, 25,000 unit/250 mL in 5% Dextrose, premixed bag, 24 count, NDC 63323-0523-74
    • Heparin Sodium solution for injection, Fresenius Kabi, 25,000 unit/500 mL in 5% Dextrose, premixed bag, 24 count, NDC 63323-0522-77
    • Heparin Sodium solution for injection, Fresenius Kabi, 25,500 unit/500 mL in 0.45% Sodium Chloride, premixed bag, 24 count, NDC 63323-0518-77
    • Heparin Sodium solution for injection, Pfizer, 1,000 unit/500 mL in 0.9% Sodium Chloride, premixed bag, 18 count, NDC 00409-7620-03
    • Heparin Sodium solution for injection, Pfizer, 25,000 unit/250 mL in 5% Dextrose, premixed bag, 24 count, NDC 00409-7793-62

Reason for the Shortage

    • Baxter has heparin premix available.
    • BBraun has heparin premixes available.
    • Fresenius Kabi had put heparin on a protective allocation due to a potential shortage of raw ingredient. The letter describing this in detail is available at the following link: https://www.fresenius-kabi.com/us/news/fresenius-kabi-responds-to-a-potential-shortage-of-heparin.
    • Pfizer has heparin on shortage due to manufacturing delays.

Available Products

    • Temporary Import solution for injection, Baxter, 1,000 units/500 mL in 0.9% sodium chloride, premixed bag, 20 count, NDC 00338-9556-20
    • Heparin Sodium solution for injection, BBraun, 1,000 unit/500 mL in 0.9% Sodium Chloride, premixed bag, 24 count, NDC 00264-9872-10
    • Heparin Sodium solution for injection, BBraun, 20,000 unit/500 mL in 5% Dextrose, premixed bag, 24 count, NDC 00264-9567-10
    • Heparin Sodium solution for injection, BBraun, 25,000 unit/250 mL in 5% Dextrose, premixed bag, 24 count, NDC 00264-9587-20
    • Heparin Sodium solution for injection, BBraun, 25,000 unit/500 mL in 5% Dextrose, premixed bag, 24 count, NDC 00264-9577-10
    • Heparin Sodium solution for injection, Baxter, 1,000 unit/500 mL in 0.9% sodium chloride, premixed bag, 18 count, NDC 00338-0424-18
    • Heparin Sodium solution for injection, Baxter, 2,000 unit/1000 mL in 0.9% sodium chloride, premixed bag, 12 count, NDC 00338-0433-04
    • Heparin Sodium solution for injection, Fresenius Kabi, 25,500 unit/250 mL in 0.45% Sodium Chloride, premixed bag, 24 count, NDC 63323-0517-74
    • Heparin Sodium solution for injection, Pfizer, 12,500 unit/250 mL in 0.45% Sodium Chloride, premixed bag, 24 count, NDC 00409-7651-62
    • Heparin Sodium solution for injection, Pfizer, 2,000 unit/1000 mL in 0.9% Sodium Chloride, premixed bag, 12 count, NDC 00409-7620-59
    • Heparin Sodium solution for injection, Pfizer, 25,000 unit/250 mL in 0.45% Sodium Chloride, premixed bag, 24 count, NDC 00409-7650-62
    • Heparin Sodium solution for injection, Pfizer, 25,000 unit/500 mL in 0.45% Sodium Chloride, premixed bag, 24 count, NDC 00409-7651-03

Estimated Resupply Dates

    • Fresenius Kabi has heparin 25,000 units/250 mL in 5% dextrose premixed bags and 25,000 units/500 mL in 5% dextrose premixed bags on back order and the company estimates a release date of early- to mid-June 2020. There are short-dated 25,000 units/500 mL in 0.45% sodium chloride premixed bags available with an expiration date of <6 months.
    • Pfizer has heparin 25,000 units/250 mL in 5% dextrose premixed bags on back order and the company estimates a release date of September 2020. The 200 units/100 mL in 0.9% sodium chloride premixed bags are available in limited supply.

Updated

Updated May 20, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 7, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.